RxDoctor Payments DataLook up a doctor →

Daniel Humiston, MD

Cardiovascular Disease · Farmington, UTNPI 1780679829

Payments from drug & device makers

$498,025in general payments, 2019–2025

Across 303 payments — averaging $1643.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$326K
  • Esperion Therapeutics, Inc.$123K
  • Amgen$47K
  • Medtronic$353
  • Boston Scientific$247
  • Abbott$125
  • plus $652 from 18 others
$8,690in research payments, 2019–2025

Across 2 payments — averaging $4345.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$9K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$498,025 in reported general payments places this provider in the 95th percentile of 131 cardiovascular disease providers in Utah.

See all cardiovascular disease providers in Utah

Medicare billing

Part B allowed, 2024
$391,411
Medicare patients
801
Services billed
3,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Farmington

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →